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This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-
related disability even in patients with a history of highly active and longstanding RA. Moreover, we found that the improvement
in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant
recovery over the subsequent four years.
1. Introduction
Rheumatoid arthritis- (RA-) related disability is one of the
major problems faced by clinicians and patients: it reduces
working capacity [1], affects the personal relationships and
lifestyles of patients and their relatives [2], and increases the
direct and indirect costs of the disease [3]. The wide range
of factors that may give rise to patient disability include
disease activity, joint damage [4], articular pain [5], and
comorbidities [6, 7]. However, despite the established impact
of disability in RA, the current treatment guidelines are
driven by evaluations of disease activity based on composite
scores such as the 28-joint disease activity score (DAS28).
Introduced in 1995 [8], the DAS28 has a cut-off value
of <2.6 defining RA remission [9] but does not include
a disability assessment. Moreover, real-life practice clearly
shows that multiple joints can remain swollen or tender, and
that pain can persist even when patients meet the remission
cut-off score [10]. It is interesting to note that a recent
large-scale observational study found disparities between
the reduction in disease activity as expressed by DAS28
scores and the progression of disability [11]. The recently
published ACR/EULAR remission criteria are also affected
by these limitations [12]. The fact that the available disease
activity scores do not necessarily correlate with structural
remission or disability therefore suggests that there is a
need for additional means of evaluation and a more detailed
consideration of the quality of remission [13].
This is particularly important because the therapeutic
approach to RA has greatly improved as a result of its
earlier diagnosis and treatment [14, 15] and the availability
of bio(techno)logical drugs such as anti-TNF𝛼 agents [16].
The European League Against Rheumatism (EULAR) rec-
ommendations stress the well-timed use of anti-TNF agents
in the case of the premature failure of traditional disease
modifying antirheumatic drugs (DMARDs) [17].
TheHealth Assessment Questionnaire (HAQ) is the most
widely used index of disability in RA: it is sensitive, effective,
reliable, cheap and rapid to administer, reflects the patients’
point of view, and correlates well with measures of chronic
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inflammation [18]. If an HAQ score is <0.5 during a year, RA
treatment can be considered very effective, but this is true
of only 38% of the patients with a DAS28 score of <2.6, and
56% of those with the HAQ a simple disease activity index
(SDAI) of <3.3 [18]. In addition, HAQ is related to working
capacity [19], the need for specialist examinations [20], and
the quoad vitam prognosis [21], and is also an appropriate
means of summarising outcomes and the direct and indirect
costs of the disease [22].
The primary aims of this study were to define the long-
term effects of anti-TNF𝛼 drugs (etanercept, adalimumab,
and infliximab) on disability in patients with early or long-
standing RA and evaluate whether an improvement in HAQ
scores correlates with an improvement in DAS28 scores.
The secondary aims included identifying the baseline factors
associated with disability, evaluating the kinetics of drug-
induced improvements in disability, and indirectly observing
whether there are differences in functional responses to the
three anti-TNF drugs.
2. Materials and Methods
The source of the data used in this study was the online Lom-
bardy Rheumatology Network (LORHEN) registry, which
contains the clinical history and demographic data of all
patients satisfying the 1987 revised American College of
Rheumatology (ACR) criteria for RA [23] attending four
Rheumatology Centres in Lombardy (Spedali Civili in Bres-
cia, Ospedale L. Sacco and Istituto G. Pini in Milan, and
Policlinico San Matteo in Pavia) since 1999 who have been
treated with bio(techno)logical drugs until last year. The
registry has been previously used as a source for other
scientific publications [24, 25]. The inclusion criteria were
beginning first-line bio(techno)logical treatment with an
anti-TNF agent (infliximab, adalimumab, or etanercept) and
at least six months of followup. The data were collected
at baseline and then every six months until a maximum
followup of 60 months (end of collection: March 2013) and
included the number of swollen and tender joints (out of 28
joints), laboratory findings (rheumatoid factor (RF), antic-
itrullinated protein antibodies (ACPAs), C-reactive protein
(CRP) levels, the erythrocyte sedimentation rate (ESR)), and
DAS28 and HAQ scores [26].
The enrolled patients were stratified on the basis of differ-
ent variables: age at the time of beginning anti-TNF𝛼 therapy
(≥65 versus <65 years); gender (males versus females); RF
(seronegative versus <3 times the upper normal limit of
42 IU/mL (low titre) versus ≥3 times the upper normal limit
(medium/high titre)); disease duration at baseline (<3, 3–5,
5–10, 10–15, or ≥15 years); disease activity at baseline assessed
on the basis of DAS28 scores (<2.6 = remission; 2.6–3.2 =
low disease activity; 3.3–5.0 = moderate disease activity; ≥5.1
= high disease activity); baseline HAQ scores (<0.5 = no
disability; 0.5–1 = mild disability; 1-2 = moderate disability;
≥2 = severe disability) [27]; the concurrent use of DMARDs
and steroids (yes versus no); the anti-TNF agents used
(infliximab, etanercept, and adalimumab); and the number
of comorbidities (1, 2, 3, or ≥4), including all comorbidities
that have a potential impact on patient disability such as
cardiovascular and lung involvement, peripheral neuropathy,
type 2 diabetes mellitus, dyslipidemia, thyroid illness, and
osteoporosis.
The improvement in disability was considered clinically
significant if it was more than the minimally important
difference (MID; HAQ > 0.22) [28].
3. Statistical Analysis
The differences between the anti-TNF agents were analysed
on the basis of the data related to all LORHEN patients
with at least a 6-month HAQ score using the Kruskal-Wallis
nonparametric test for continuous variables (mean values and
standard deviations) and the chi-squared test for categorical
variables (absolute numbers and percentages). The changes
from baseline were analysed using Wilcoxon’s signed-rank
test. The multivariate analyses were made using stepwise
logistic regression models, with the response variable being
defined as a >0.5 decrease in HAQ scores after one and five
years. All of the analyses were made using SAS version 9.2
(SAS Institute, Inc., Cary, NC), and a 𝑃 value of 0.05 or less
was considered statistically significant.
All of the statistical analyses excluded patients with
missing data.
4. Results
The LORHEN registry includes 1381 patients satisfying the
1987 revised ACR criteria for RA [24]. We considered only
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those receiving infliximab, adalimumab, or etanercept as a
first-line bio(techno)logical drug.
The final study population consisted of 1033 patients (847
females, 186 males) whose baseline clinical and demographic
characteristics are shown in Tables 1 and 2. At the end of the
study, 42% of the patients were still receiving an anti-TNF𝛼
agent (Figure 3). Disability as assessed on the basis of their
HAQ scores significantly decreased in all cases (ΔHAQ−0.78;
𝑃 < 0.05): at the end of the followup, the HAQ score was
0.69 (mild disability) as against 1.42 at baseline (moderate
disability). Furthermore, 193/904 patients (21.35%) had no
disability (HAQ < 0.5) after one year and 123/344 (35.75%)
after five years of followup.
The change in HAQ scores over time had a biphasic
course (Figure 1), with a rapid clinical improvement in the
first year (ΔHAQ 0-1: −0.53; 𝑃 < 0.05), followed by a
further slower improvement that did not become clinically or
statistically significant until the end of the followup (ΔHAQ
1–5: −0.25; 𝑃 < 0.05). The functional improvement was even
more striking (ΔHAQ 0–5: −0.81; 𝑃 < 0.05) among the 459
patients in clinical remission (44.43%; DAS28 < 2.6), and
there was no disability after the 30th month of followup.
Interestingly, there was a temporal dissociation between the
time of clinical remission (21st month) and the time of
maximum functional improvement (60th month).
The population was then stratified on the basis of the
various clinical and demographic variables described in the
Methods section, and the results are shown in Table 3.
The 847 females (82%) had greater disability at baseline than
the 186 males (18%) (ΔHAQ > MID; 𝑃 < 0.05), and this
difference was even greater at the end of the followup period.
The 245 patients aged ≥65 years (25.76%) showed greater
disability at baseline (ΔHAQ >MID; 𝑃 < 0.05) than the 788
patients aged 18–64 years (74.24%), and their improvement
during followup was less striking.
The seronegative patients (75/668, 11.22%) and those with
a low RF titre (110/668, 16.47%) showed similar disability
at baseline and similarly improved during the five years
of biological treatment (HAQ < MID; 𝑃: ns), whereas the
baseline disability of the patients with a high titre (483/668,
72.31%) was worse (ΔHAQ >MID; 𝑃 < 0.05) and remained
so until the end of the followup.
The between-group differences in disease duration before
the start of anti-TNF therapy (<3 years: 412/1017, 40.52%; 3–
5 years: 105/1017, 10.32%; 5–10 years: 181/1017, 17.8%; 10–15
years: 140/1017, 13.76%; and >15 years: 179/1017, 17.6%) were
significant at baseline and remained so until the end of the
followup (ΔHAQ >MID; 𝑃 < 0.05): in particular the longer
the disease duration, the worse the disability.
The patients with higher baseline HAQ and DAS28
scores showed worse disability and achieved a less significant
improvement (ΔHAQ > MID; 𝑃 < 0.05). The disability
subgroups were HAQ < 0.5: 53/1018, 5.2%; 0.5–1: 161/1018,
15.82%; 1-2: 599/1018, 58.85%; and ≥2: 205/1018, 20.13%. The
disease activity subgroups were DAS28 < 3.2: 30/1021, 2.93%;
3.2–5.1: 218/1021, 21.36%; ≥5.1: 773/1021, 75.71%.
The patients were stratified into four subgroups on the
basis of the number of comorbidities: 380/704 (53.98%)
had one, 188/704 (26.7%) two, 86/704 (12.22%) three, and
Table 1: Baseline clinical data of the 1033 study patients.
HAQ (SD) 1.42 ± 0.61
DAS28 (SD) 5.73 ± 1.15
High 773 (74.83%)
Moderate 218 (21.1%)
Low 15 (1.45%)
Remission 15 (1.45%)
Missing 12 (1.16%)
Steinbrocker functional class I 37 (3.58%)
II 706 (68.34%)
III 247 (23.91%)
IV 37 (3.58%)
Missing 6 (0.58%)
Pain visual analogue scale (SD) 62.09 ± 22.68
Global health assessment (SD) 59.81 ± 22.47
Swollen joint count (SD) 9.73 ± 5.54
Tender joint count (SD) 10.8 ± 6.49
Anti-TNF drugs
Adalimumab 305 (29.53%)
Etanercept 231 (22.36%)
Infliximab 497 (48.11%)
Number of previous DMARDs
1 67 (6.49%)
2 364 (35.24%)
3 309 (29.91%)
4 172 (16.65%)
≥5 113 (10.94%)
HAQ: Health Assessment Questionnaire; DAS28: 28-joint disease activ-
ity score; TNF: tumour necrosis factor; DMARDS: disease modifying
antirheumatic drugs; SD: standard deviation.
Table 2: Baseline demographic data.
F/M 847/186 (81.99%)
Age at diagnosis (SD) 46.79 ± 14.62
Age at anti-TNF start, years (SD) 55.12 ± 13.4
Disease duration, years (SD) 7.68 ± 8.15
Comorbidities 704/1033 (68.15%)
F: female; M: male; SD: standard deviation.
50/704 (7.1%) four or more. The presence of comorbidities
significantly reduced the recovery of joint function during
anti-TNF treatment: the greater the number of comorbidities,
the worse the improvement in disability (ΔHAQ >MID; 𝑃 <
0.05).
The baseline difference between the patients receiving
steroids (867/1033, 83.93%) or not (166/1033, 16.07%) was
statistically significant (ΔHAQ > MID; 𝑃 < 0.05), but there
was no difference after 42 months (ΔHAQ >MID; 𝑃 = ns).
The patients concurrently receiving DMARDs (950/1033,
91.94%) showed a better functional recovery than those
receiving monotherapy (83/1033, 8.03%), and the difference
became significant after 30 months of followup (ΔHAQ >
MID; 𝑃 < 0.05).
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Baseline 6th month
12th 
month
18th 
month
24th 
month
30th 
month
36th 
month
42nd 
month
48th 
month
54th 
month
60th 
month
No switch
Switch
H
AQ
1.41 0.97 0.84 0.81 0.75 0.68 0.71 0.63 0.65 0.57 0.6
1.11 1.04 0.96 0.96 0.89 0.890.94 0.94 0.940.921.47
Figure 2
LORHEN registry
(RA diagnosis and HAQ
at baseline)
n = 1381
HAQ at least at 6th month
n = 1033
HAQ only at baseline
n = 348
Patients included
n = 1033
HAQ up to 60th month
n = 344
Figure 3
In relation to the anti-TNF𝛼 agents used (infliximab,
494/1022, 48.34%; etanercept 227/1022, 22.21%; and adali-
mumab 301/1022, 29.45%), the patients treated with inflix-
imab had worse baseline disability (ΔHAQ >MID;𝑃 < 0.05),
but the difference became nonsignificant after two years of
anti-TNF treatment (ΔHAQ >MID; 𝑃 = ns).
Twohundred and seventy-five patients (26.62%) switched
from the first to a second TNF blocker because of a secondary
lack of effectiveness (58.55%), adverse events (30.55%), or
other reasons (10.9%): themost frequently discontinued drug
was infliximab, which was most frequently replaced by etan-
ercept.The patients who did not need to modify their biolog-
ical treatment had less residual disability than those who had
to switch (HAQ 0.6 versus 0.89; 𝑃 < 0.05) (Figure 2), but the
improvement inHAQ scores was significant after five years of
followup in both subgroups (ΔHAQ >MID; 𝑃 < 0.05).
Multivariate analyses identified the baseline variables
correlated with a more than 0.5 decrease in HAQ scores after
one and five years.The patients whowere less likely to achieve
an optimal functional recovery were mainly females, aged
more than 65 years, had a baseline DAS28 score of >5.1, and
were not taking steroids (Table 4). Functional recovery after
five years was reduced in the patients treated with etanercept
or adalimumab.
It was impossible to include the other variables in the
multivariate analyses because of the missing data.
5. Discussion
Our results confirm the effectiveness of etanercept, adal-
imumab, and infliximab in reducing RA-related disabil-
ity even in patients with a history of highly active and
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Table 4: Univariate and multivariate analyses of baseline characteristics predicting complete disability recovery (HAQ < 0.5).
HAQ < 0.5 (1st year) Univariate analysis HAQ < 0.5 (1st year) Multivariate analysis
OR (95% CI) 𝑃 OR (95% CI) 𝑃
Age (≥65 versus <65 years) [0.974 (0.962–0.985)] <0.0001 Age (≥65 versus <65 years) [0.978 (0.965–0.99)] 0.0004
Gender (F versus M) [0.354 (0.248–0.505)] <0.0001 Gender (F versus M) [0.417 (0.282–0.617)] <0.0001
Disease duration (years) [1.004 (0.985–1.023)] ns Disease duration [0.998 (0.976–1.02)] ns
DAS28 (high versus
moderate versus low) [0.622 (0.542–0.713)] <0.0001
DAS28 (high versus
moderate versus low) [0.724 (0.626–0.837)] <0.0001
DMARDs (no versus yes) [1.248 (0.724–2.151)] ns DMARDs (no versus yes) [0.85 (0.453–1.596)] ns
Steroids (no versus yes) [2.109 (1.445–3.078)] 0.0001 Steroids (no versus yes) [1.775 (1.153–2.734)] ns
Adalimumab versus
infliximab [1.495 (1.045–2.138)] ns
Adalimumab versus
infliximab [1.547 (1.041–2.297)] 0.0307
Etanercept versus
infliximab [1.048 (0.69–1.59)] ns
Etanercept versus
infliximab [0.871 (0.538–1.41)] ns
HAQ < 0.5 (5th year) Univariate analysis HAQ < 0.5 (5th year) Univariate analysis
OR (95% CI) 𝑃 OR (95% CI) 𝑃
Age (≥65 versus <65 years) [0.978 (0.964–0.991)] 0.0014 Age (≥65 versus <65 years) [0.982 (0.967–0.996)] 0.0142
Gender (F versus M) [0.474 (0.31–0.726)] 0.0006 Gender (F versus M) [0.571 (0.362–0.901)] 0.016
Disease duration [1.002 (0.979–1.025)] ns Disease duration [0.995 (0.97–1.022)] ns
DAS28 (high versus
moderate versus low) [0.729 (0.624–0.853)] 0.0001
DAS28 (high versus
moderate versus low) [0.79 (0.668–0.936)] 0.0063
DMARDs (no versus yes) [0.702 (0.322–1.53)] ns DMARDs (no versus yes) [0.627 (0.255–1.54)] ns
Steroids (no versus yes) [1.851 (1.182–2.898)] 0.0071 Steroids (no versus yes) [1.832 (1.102–3.045)] 0.0195
Adalimumab versus
Infliximab [0.607 (0.383–0.962)] ns
Adalimumab versus
infliximab [0.554 (0.337–0.911)] 0.0199
Etanercept versus
infliximab [0.607 (0.364–1.011)] ns
Etanercept versus
infliximab [0.502 (0.284–0.888)] 0.0179
OR: odds ratio; CI: confidence interval; F: female; M: male; DMARDs: disease modifying antirheumatic drugs; DAS28: 28-joint disease activity score; HAQ:
Health Assessment Questionnaire.
long-standing RA. Similar findings have been reported in
other, shorter observational studies [29, 30]. As suggested
by Aletaha and Ward, we can also confirm that patients
can achieve a good functional recovery even after years of
illness because the reversible factors underlying HAQ scores
(pain and inflammation) tend to prevail over joint damage
[31]. Starting anti-TNF therapy not only generally reduced
disability frommoderate to mild, but also led to patients who
achieved clinical remission during the followup (DAS28 score
<2.6) completely recovering fromdisability (HAQ score<0.5)
regardless of disease duration. Randomised clinical trials
have shown that the well-timed use of biological treatment
in the case of early failure with traditional DMARDs should
induce the complete remission of functional dysfunction [32,
33], but these findings require confirmation in further studies
aimed at this primary endpoint.
We found that the improvement in disabilitywas biphasic,
with a marked improvement during the first year of anti-
TNF therapy, followed by slower but significant recovery over
the subsequent four years. This was typically observed when
a “step-up” therapeutic strategy was adopted and, in this case,
it is important to wait five years for the stabilisation of HAQ
scores in patients with long-standing RA. More aggressive
and earlier treatment leads to a rapid phase of improvement
(a J-shaped curve) and subsequent stabilisation after one year
[24]. However, it is not enough to consider a state of clinical
remission defined on the basis of DAS criteria because, in
our study, DAS28 remission was observed an average of 21
months after the start of anti-TNF treatment, whereas it took
five years before the improvement in HAQ scores was at its
peak.
It is interesting to note that there was a clinical and
statistical improvement in HAQ scores in all of the analysed
groups during followup, although the results were less strik-
ing in patients aged ≥65 years, females, and those with a
disease duration of more than 10 years, a higher comorbidity
index, greater disease activity and disability, a high RF titre,
or contraindications to combination therapy with traditional
DMARDs. The chronic use of low-dose steroids seemed to
contribute to reducing disability in the patients with greater
impairment at baseline.
As expected, the patients treated with infliximab (the
first biological treatment available in Italy) showed greater
disability at baseline, but their improvement was better than
that of the patients treated with etanercept or adalimumab.
The univariate and multivariate analyses confirmed that
age (≥65 years), female gender, a DAS28 score of >5.1, and no
use of steroids correlated with a lower level of recovery from
disability during anti-TNF therapy. Although the probability
of drug withdrawal was greater with infliximab, the use
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of etanercept and adalimumab was also associated with a
reduced probability of functional recovery, but this was only
evident after five years of treatment. Disease duration does
not seem to be a negative predictor.
One final aspect emerging from our study concerns
switching from one anti-TNF agent to another: the results
in the patients who had to switch because of inefficacy or
adverse events were less striking than those in the patients
who continued on the same drug. These findings are similar
to those of other observational studies [16], but the effect on
disability of using a drugwith a differentmechanismof action
from the first still remains to be explored.
Recent studies have stressed the importance ofmeasuring
functional ability and considering it when making decisions
concerning patient management. A Canadian observational
study of 1086 RA patients (799 treated with anti-TNF agents)
found that the annual mean (direct and indirect) costs of the
disease were directly proportional to disability as measured
by means of the HAQ: the costs were three times higher for
patients with severe disability (HAQ > 2) than for patients
without disability (HAQ < 0.5), with working disability being
the major indirect cost [34]. Data from the British registry
indicates that half of all biological agent-naı¨ve RApatients are
unable to work: HAQ scores closely correlated with working
capacity, with patients who were severely disabled at baseline
being more likely to become work disabled at followup [35].
The main strengths of our study are the large number
and the heterogeneity of the enrolled patients, and the
long-term followup. However, it also has some important
limitations. First of all, as it was an observational study, there
may be some patient selection bias. Secondly, RA disability
was evaluated without using radiological parameters, and
some other parameters (cigarette smoking, ACPAs) were not
statistically analysed because there were too many missing
data.
6. Conclusions
The effect of anti-TNF therapy on the disability of patients
with RA is certainly substantial also in the case of long-
standing disease and, in addition to other clinimetric indices
such as the DAS28, HAQ scores are a good means of
evaluating the efficacy of biological treatment.
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